Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal

All NewsMarch 20, 2025

Alvotech acquires Xbrane’s R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities and expanding into Sweden.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent